Global Myasthenia Gravis Disease Treatment Market Size, Status, Research and Forecast 2019-2025

Published On: Jul 2019

Format: PDF

Publisher: QY Research

Pages: 106

Report ID: 3002

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.
In 2018, the global Myasthenia Gravis Disease Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Myasthenia Gravis Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Myasthenia Gravis Disease Treatment development in United States, Europe and China.

The key players covered in this study
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie
Valeant Pharmaceuticals
Sun Pharmaceuticals
Fresenius Kabi
Piramal Healthcare
RPG Life Sciences

Market segment by Type, the product can be split into
Medication
Surgery
Others

Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Myasthenia Gravis Disease Treatment status, future forecast, growth opportunity, key market and key players.
To present the Myasthenia Gravis Disease Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Myasthenia Gravis Disease Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Myasthenia Gravis Disease Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Medication
1.4.3 Surgery
1.4.4 Others
1.5 Market by Application
1.5.1 Global Myasthenia Gravis Disease Treatment Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Myasthenia Gravis Disease Treatment Market Size
2.2 Myasthenia Gravis Disease Treatment Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Treatment Market Size by Regions (2014-2025)
2.2.2 Myasthenia Gravis Disease Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Myasthenia Gravis Disease Treatment Market Size by Manufacturers
3.1.1 Global Myasthenia Gravis Disease Treatment Revenue by Manufacturers (2014-2019)
3.1.2 Global Myasthenia Gravis Disease Treatment Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Myasthenia Gravis Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Myasthenia Gravis Disease Treatment Key Players Head office and Area Served
3.3 Key Players Myasthenia Gravis Disease Treatment Product/Solution/Service
3.4 Date of Enter into Myasthenia Gravis Disease Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Myasthenia Gravis Disease Treatment Market Size by Type (2014-2019)
4.2 Global Myasthenia Gravis Disease Treatment Market Size by Application (2014-2019)

5 United States
5.1 United States Myasthenia Gravis Disease Treatment Market Size (2014-2019)
5.2 Myasthenia Gravis Disease Treatment Key Players in United States
5.3 United States Myasthenia Gravis Disease Treatment Market Size by Type
5.4 United States Myasthenia Gravis Disease Treatment Market Size by Application

6 Europe
6.1 Europe Myasthenia Gravis Disease Treatment Market Size (2014-2019)
6.2 Myasthenia Gravis Disease Treatment Key Players in Europe
6.3 Europe Myasthenia Gravis Disease Treatment Market Size by Type
6.4 Europe Myasthenia Gravis Disease Treatment Market Size by Application

7 China
7.1 China Myasthenia Gravis Disease Treatment Market Size (2014-2019)
7.2 Myasthenia Gravis Disease Treatment Key Players in China
7.3 China Myasthenia Gravis Disease Treatment Market Size by Type
7.4 China Myasthenia Gravis Disease Treatment Market Size by Application

8 Japan
8.1 Japan Myasthenia Gravis Disease Treatment Market Size (2014-2019)
8.2 Myasthenia Gravis Disease Treatment Key Players in Japan
8.3 Japan Myasthenia Gravis Disease Treatment Market Size by Type
8.4 Japan Myasthenia Gravis Disease Treatment Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Myasthenia Gravis Disease Treatment Market Size (2014-2019)
9.2 Myasthenia Gravis Disease Treatment Key Players in Southeast Asia
9.3 Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Type
9.4 Southeast Asia Myasthenia Gravis Disease Treatment Market Size by Application

10 India
10.1 India Myasthenia Gravis Disease Treatment Market Size (2014-2019)
10.2 Myasthenia Gravis Disease Treatment Key Players in India
10.3 India Myasthenia Gravis Disease Treatment Market Size by Type
10.4 India Myasthenia Gravis Disease Treatment Market Size by Application

11 Central & South America
11.1 Central & South America Myasthenia Gravis Disease Treatment Market Size (2014-2019)
11.2 Myasthenia Gravis Disease Treatment Key Players in Central & South America
11.3 Central & South America Myasthenia Gravis Disease Treatment Market Size by Type
11.4 Central & South America Myasthenia Gravis Disease Treatment Market Size by Application

12 International Players Profiles
12.1 GlaxoSmithKline
12.1.1 GlaxoSmithKline Company Details
12.1.2 Company Description and Business Overview
12.1.3 Myasthenia Gravis Disease Treatment Introduction
12.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.1.5 GlaxoSmithKline Recent Development
12.2 Novartis
12.2.1 Novartis Company Details
12.2.2 Company Description and Business Overview
12.2.3 Myasthenia Gravis Disease Treatment Introduction
12.2.4 Novartis Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.2.5 Novartis Recent Development
12.3 Teva Pharmaceutical
12.3.1 Teva Pharmaceutical Company Details
12.3.2 Company Description and Business Overview
12.3.3 Myasthenia Gravis Disease Treatment Introduction
12.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.3.5 Teva Pharmaceutical Recent Development
12.4 Roche
12.4.1 Roche Company Details
12.4.2 Company Description and Business Overview
12.4.3 Myasthenia Gravis Disease Treatment Introduction
12.4.4 Roche Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.4.5 Roche Recent Development
12.5 Bristol-Myers Squibb
12.5.1 Bristol-Myers Squibb Company Details
12.5.2 Company Description and Business Overview
12.5.3 Myasthenia Gravis Disease Treatment Introduction
12.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.5.5 Bristol-Myers Squibb Recent Development
12.6 Apotex
12.6.1 Apotex Company Details
12.6.2 Company Description and Business Overview
12.6.3 Myasthenia Gravis Disease Treatment Introduction
12.6.4 Apotex Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.6.5 Apotex Recent Development
12.7 Cipla
12.7.1 Cipla Company Details
12.7.2 Company Description and Business Overview
12.7.3 Myasthenia Gravis Disease Treatment Introduction
12.7.4 Cipla Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.7.5 Cipla Recent Development
12.8 Biogen
12.8.1 Biogen Company Details
12.8.2 Company Description and Business Overview
12.8.3 Myasthenia Gravis Disease Treatment Introduction
12.8.4 Biogen Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.8.5 Biogen Recent Development
12.9 AbbVie
12.9.1 AbbVie Company Details
12.9.2 Company Description and Business Overview
12.9.3 Myasthenia Gravis Disease Treatment Introduction
12.9.4 AbbVie Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.9.5 AbbVie Recent Development
12.10 Valeant Pharmaceuticals
12.10.1 Valeant Pharmaceuticals Company Details
12.10.2 Company Description and Business Overview
12.10.3 Myasthenia Gravis Disease Treatment Introduction
12.10.4 Valeant Pharmaceuticals Revenue in Myasthenia Gravis Disease Treatment Business (2014-2019)
12.10.5 Valeant Pharmaceuticals Recent Development
12.11 Sun Pharmaceuticals
12.12 Fresenius Kabi
12.13 Piramal Healthcare
12.14 RPG Life Sciences

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details